Citadel Advisors - SANGAMO THERAPEUTICS INC ownership

SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 195 filers reported holding SANGAMO THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.58 and the average weighting 0.0%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of SANGAMO THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,816,910
-52.9%
4,696,415
+2.2%
0.00%0.0%
Q2 2023$5,974,687
+2.2%
4,595,913
+38.3%
0.00%0.0%
Q1 2023$5,848,392
+19.6%
3,322,950
+113.4%
0.00%0.0%
Q4 2022$4,890,066
+70.8%
1,557,346
+166.5%
0.00%
Q3 2022$2,863,000
-12.2%
584,355
-25.8%
0.00%
-100.0%
Q2 2022$3,261,000
-19.6%
787,903
+12.9%
0.00%0.0%
Q1 2022$4,055,000
-49.2%
697,808
-34.4%
0.00%0.0%
Q4 2021$7,979,000
+12.3%
1,063,916
+35.0%
0.00%
-50.0%
Q3 2021$7,103,000
-51.7%
788,310
-35.9%
0.00%
-33.3%
Q2 2021$14,710,000
-34.9%
1,228,869
-31.9%
0.00%
-40.0%
Q1 2021$22,606,000
+18.4%
1,804,223
+47.5%
0.01%0.0%
Q4 2020$19,091,000
+4.8%
1,223,377
-36.6%
0.01%
-16.7%
Q3 2020$18,221,000
+104.3%
1,928,150
+93.7%
0.01%
+100.0%
Q2 2020$8,920,000
-35.0%
995,456
-53.8%
0.00%
-50.0%
Q1 2020$13,723,000
+23.6%
2,154,419
+62.4%
0.01%0.0%
Q4 2019$11,104,000
-51.0%
1,326,619
-47.0%
0.01%
-45.5%
Q3 2019$22,671,000
-11.6%
2,505,115
+5.2%
0.01%0.0%
Q2 2019$25,656,000
+260.1%
2,382,182
+219.0%
0.01%
+266.7%
Q1 2019$7,124,000
-25.6%
746,692
-10.5%
0.00%
-40.0%
Q4 2018$9,575,000
-51.5%
834,037
-28.3%
0.01%
-44.4%
Q3 2018$19,728,000
+105.5%
1,163,961
+72.2%
0.01%
+80.0%
Q2 2018$9,600,000
-7.3%
676,053
+24.0%
0.01%0.0%
Q1 2018$10,361,000
+17.9%
545,290
+1.7%
0.01%0.0%
Q4 2017$8,791,000
+18.7%
536,048
+8.6%
0.01%0.0%
Q3 2017$7,404,000
-41.7%
493,595
-65.8%
0.01%
-50.0%
Q2 2017$12,692,000
+2872.4%
1,442,301
+1654.7%
0.01%
Q1 2017$427,000
-37.7%
82,198
-63.4%
0.00%
Q4 2016$685,000
+30.0%
224,600
+97.5%
0.00%
Q3 2016$527,000
+584.4%
113,735
+797.1%
0.00%
Q1 2016$77,000
+600.0%
12,678
+929.9%
0.00%
Q4 2015$11,000
-94.9%
1,231
-96.8%
0.00%
Q3 2015$217,000
-78.4%
38,394
-40.0%
0.00%
-100.0%
Q1 2015$1,003,000
-60.1%
64,010
-61.3%
0.00%
-50.0%
Q4 2014$2,514,000
+63.4%
165,282
+15.8%
0.00%0.0%
Q3 2014$1,539,000
-40.2%
142,729
-15.4%
0.00%
-33.3%
Q2 2014$2,575,000
+113.2%
168,693
+152.6%
0.00%
+200.0%
Q1 2014$1,208,000
+23.1%
66,795
-5.5%
0.00%0.0%
Q4 2013$981,000
+654.6%
70,682
+469.7%
0.00%
Q3 2013$130,000
+68.8%
12,406
+25.9%
0.00%
Q2 2013$77,0009,8500.00%
Other shareholders
SANGAMO THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Lombard Odier Asset Management (Switzerland) SA 1,539,994$11,550,0000.74%
Golden State Equity Partners 143,768$1,078,0000.54%
Rhenman & Partners Asset Management AB 765,000$5,975,0000.40%
WASATCH ADVISORS LP 10,960,982$82,207,0000.34%
KLK CAPITAL MANAGEMENT LLC 44,323$332,0000.32%
EMC Capital Management 61,394$460,0000.25%
Rokos Capital Management LLP 539,860$4,108,0000.25%
Long Focus Capital Management, LLC 245,000$1,838,0000.24%
Vanguard Capital Wealth Advisors 33,380$250,0000.18%
Fort Sheridan Advisors LLC 74,898$562,0000.16%
View complete list of SANGAMO THERAPEUTICS INC shareholders